Skip to content

The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors

Randomized Controlled Trial of Sitting Time Interventions in Breast Cancer Survivors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02510430
Enrollment
59
Registered
2015-07-29
Start date
2015-11-30
Completion date
2018-01-24
Last updated
2018-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Brief summary

Excessive sitting time (sedentary time) has been associated with risk of insulin resistance and other factors which may be relevant to breast cancer prognosis. This 8-week study tests different strategies for helping breast cancer survivors to modify their levels of sitting time. Participants will be assigned with equal likelihood to one of three groups (1) overall reduction in sitting time, (2) interruption of sitting time with standing breaks, and (3) usual care.

Interventions

BEHAVIORALRe-Patterning Sitting Time Group

This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.

BEHAVIORALReducing Sitting Time Group

This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.

BEHAVIORALUsual Care

This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

1. diagnosed with Stage 0-III breast cancer. Bilateral or multiple primary breast cancers are permitted. 2. Completed primary treatment defined as definitive surgery, (neo)adjuvant chemotherapy and/or (neo)adjuvant radiation. Participants still receiving adjuvant endocrine or HER2 targeted therapies are eligible. 3. Report sitting for ≥8 accumulated waking hours on a typical day, 4. Willing and able to attend 3 study visits at the UW, 5. Willing to attempt reduction of sitting time, 6. Use the internet on a regular basis, 7. Willing and able to complete study requirements, and 8. Currently considered postmenopausal (no menstrual periods in past 12 months), even if pre-menopausal at diagnosis.

Exclusion criteria

1. Evidence of recurrence or metastatic disease, 2. Unable to move from sitting to standing without difficulty and to walk 1 block.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility as measured by recruitment and retention rates12 monthsFeasibility of recruiting participants to the study

Secondary

MeasureTime frameDescription
Sedentary behavior as measured by ActivPal7 daysSedentary time as measured by the ActivPAL inclinometer
Physical activity as measured by ActiGraph7 daysPhysical activity as measured by the ActiGraph accelerometer
Sedentary time as measured by ActiGraph7 daysSedentary time as measured by the ActiGraph accelerometer

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026